Lv1
18 积分 2025-12-31 加入
Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point
23天前
已完结
Considerations for using eGFR Slope as an End Point in Clinical Trials
23天前
已完结
eGFR slope in kidney hierarchical composite endpoints
23天前
已完结
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
23天前
已完结
Endothelin Receptor Antagonist Ambrisentan, SGLT2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy
24天前
已完结
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
25天前
已完结
Alternative Complement Pathway, Iptacopan, and IgA Nephropathy
1个月前
已完结
The expanding role of complement inhibitors in the treatment of IgA nephropathy
1个月前
已完结
Navigating Renin-Angiotensin System Inhibitors in Patients with Declines in eGFR
1个月前
已关闭
Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR
1个月前
已完结
皖公网安备34019202002308
